What does this score mean?
The Confidence Index does not indicate the success rate of the treatment, but editorial confidence in the clinical conclusion that can be drawn from the available data. Study design, sample size, peer-reviewed publication status, direct clinical comparison, and safety data were evaluated together.
Brief conclusion: Individuals who switched from injection-based weight loss treatment to daily oral semaglutide lost an average of an additional 4.1% of body weight in the following three months. However, because there was no control group, it cannot be said that this loss was directly caused by the change in formulation.
What did the study ask?
For patients who do not want to use injections or prefer a tablet form in obesity treatment, the fundamental question is: does weight loss continue when switching from an effective injectable treatment to oral semaglutide?
Real-world cohort
In the study presented at EASD 2026, 194 individuals who had previously used injectable weight loss treatment and switched to daily oral semaglutide were evaluated. The dataset was obtained from real-world follow-up conducted with a telehealth service.
What was found?
In the three months after the switch, average additional weight loss was reported as 4.1%, approximately 4 kg. Approximately 41% of participants achieved at least 5% additional body weight loss. The proportion of individuals in the clinical obesity category also decreased during the follow-up period.
Why is this result interesting?
The result suggests that the oral form may not only be an “alternative to injection,” but an option that could maintain treatment continuity in some patients. In terms of medication adherence, this could be important for individuals who prefer tablets.
But why can’t we establish causality?
The study is not randomized controlled. Because there was no similar control group that continued on injections, we cannot distinguish whether the three-month additional weight loss resulted from the switch to the oral form, the ongoing biological effect of the previous treatment, lifestyle changes, or the characteristics of the selected patient group.
Furthermore, part of the data relies on patient self-reporting. Real-world data are valuable for understanding clinical practice, but are more open to issues such as measurement standardization and loss to follow-up.
What does it mean clinically?
This study supports that, in appropriate patients, switching from injection to oral semaglutide does not necessarily mean weight loss will stop. However, the result should not be interpreted as “the oral form is more effective than the injection.” A randomized head-to-head switch study is needed for such a claim.
Which questions are important in practice?
The decision to switch should not be evaluated solely based on the percentage of weight loss, but together with gastrointestinal tolerability, adherence to dosing instructions, accompanying diabetes treatments, cost/access, and patient preference.
References
Reuters, September 30, 2026. Patients switching to Wegovy pill from shots lose more weight in real-world study.
Medical evaluation: This content has been prepared for the purpose of evaluating scientific research; it is not a personal diagnosis or treatment recommendation. Investigational drugs should not be interpreted as approved treatments. · All Scientific Research
